TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25304187

Group type: EXPERIMENTAL
Intervention: Antenatal distribution of misoprostol (for self-administration after home birth or when oxytocin is not available)
Number of subjects: 2436

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 2436
Study: 22330022

Group type: EXPERIMENTAL
Intervention: Behavioral weight management intervention
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Structured physical activity at 12 months
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity at 24 months
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 225
Study: 19164497

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balanced amino acid drink (BAL)
Number of subjects: 0
Study: 17538513

Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 16235179

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted indinavir and efavirenz with stavudine
Number of subjects: 78

Group type: COMPARATOR
Intervention: Ritonavir-boosted indinavir and efavirenz without stavudine
Number of subjects: 78
Study: 12377839

Group type: EXPERIMENTAL
Intervention: Telephone-based special intervention (SI; n = 36) for 8 weeks (average session length, 16.3 min)
Number of subjects: 71
Study: 10416141

Group type: EXPERIMENTAL
Intervention: Prolonged second stage of labor (mean: 189 minutes)
Number of subjects: 5241

Group type: COMPARATOR
Intervention: Short second stage of labor (mean: 19 minutes)
Number of subjects: 5241
Study: 8551485

Group type: EXPERIMENTAL
Intervention: Verapamil 120-240 mg once daily for 8 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 2272345

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 7008821

Group type: EXPERIMENTAL
Intervention: Azatadine maleate (4 mg/day for 1 week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30357660

Group type: EXPERIMENTAL
Intervention: Pay-one condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pay-all condition
Number of subjects: 0
Study: 30103400

Group type: EXPERIMENTAL
Intervention: Omnivore (OM) breakfast
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lacto-Ovo Vegetarian (LOV) breakfast
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Vegan (VE) breakfast
Number of subjects: 32
Study: 27333048

Group type: EXPERIMENTAL
Intervention: E-learning group
Number of subjects: 332

Group type: COMPARATOR
Intervention: Non-e-learning group
Number of subjects: 332
Study: 25051173

Group type: EXPERIMENTAL
Intervention: Pomegranate extract (PE)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 19
Study: 22002564

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy concurrent with letrozole 2.5 mg (study arm, n = 50)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy alone (control arm, n = 51)
Number of subjects: 101
Study: 19307972

Group type: EXPERIMENTAL
Intervention: Propofol target-controlled infusion based on a weight adjustment formula (group adjusted)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Propofol target-controlled infusion without adjustment (group total body weight - TBW)
Number of subjects: 24
Study: 18004169

Group type: EXPERIMENTAL
Intervention: Triage room
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Standing orders in common obstetric problems
Number of subjects: 398

Group type: COMPARATOR
Intervention: Standard care labor room
Number of subjects: 398
Study: 14993502

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (1.5-2.0 mg/kg/day for 12 months) and steroids (methylprednisolone pulses 3 x 1 g, i.v. at months 1, 3 and 5, and oral prednisone 0.5 mg/kg/48 h for 6 months)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Historical control group (not specified treatment)
Number of subjects: 65
Study: 12145596

Group type: EXPERIMENTAL
Intervention: Stiffening device activated
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Stiffening device with magnetic endoscope imaging
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Variable-stiffness device overall
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (no stiffening device)
Number of subjects: 175
Study: 10413065

Group type: EXPERIMENTAL
Intervention: Rilmenidine (1 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7587730

Group type: EXPERIMENTAL
Intervention: Automated cell counters (Technicon H*1, TOA NE8000, Coulter STKS, Abbott CD3000)
Number of subjects: 524

Group type: COMPARATOR
Intervention: Traditional eye count differential
Number of subjects: 524
Study: 2239778

Group type: EXPERIMENTAL
Intervention: Vegetable-protein mixed diet at 96, 128, 160, and 192 mg N.kg body wt‐1.d‐1 for 10 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Milk-egg protein diet at 160 mg N.kg‐1.d‐1 for 10 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Suggested protein recommended allowance
Number of subjects: 8
Study: 348260

Group type: EXPERIMENTAL
Intervention: Metoprolol 300 mg in a single daily dose
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Metoprolol 300 mg/day in three doses
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31996259

Group type: EXPERIMENTAL
Intervention: Group interventions
Number of subjects: 5
Study: 30515719

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Platinum-based chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study: 27941119

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin, 2 times daily for 7 days
Number of subjects: 849

Group type: COMPARATOR
Intervention: Placebo, 2 times daily for 7 days
Number of subjects: 849

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin
Number of subjects: 849
Study: 24828121

Group type: EXPERIMENTAL
Intervention: Text messaging while driving
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Eating while driving
Number of subjects: 28

Group type: COMPARATOR
Intervention: Drinking 400 mL water
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Drinking 400 mL water and eating a 6-inch Subway sandwich
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Drinking 400 mL water and composing 3 text messages
Number of subjects: 28
Study: 23421352

Group type: EXPERIMENTAL
Intervention: 40 IU intranasal oxytocin for 10 consecutive days
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo for 10 consecutive days
Number of subjects: 41
Study: 21030410

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% eye drops, 4 times per day for 2 days, plus 2 drops 30 min apart 1 hour prior to surgery
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% eye drops, 4 times per day for 2 days, plus 4 drops 10 min apart 1 hour prior to surgery
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.3% eye drops, 4 times per day for 2 days, plus 2 drops 30 min apart 1 hour prior to surgery
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.3% eye drops, 4 times per day for 2 days, plus 4 drops 10 min apart 1 hour prior to surgery
Number of subjects: 97
Study: 19169446

Group type: EXPERIMENTAL
Intervention: 0.2% solution of CHX
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.12% solution of CHX
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.2% gel
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.2% spray
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.12% spray
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: swab with 0.2% solution
Number of subjects: 10
Study: 15781531

Group type: EXPERIMENTAL
Intervention: Heparinized flush solution (group H, n = 100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nonheparinized flush solution (group S, n = 100)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Heparinized flush solution (group H)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nonheparinized flush solution (group S)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study: 10551070

Group type: EXPERIMENTAL
Intervention: Guided bone regeneration with e‐PTFE membranes supported by stainless steel screws and autologous bone chips (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Autologous bone blocks taken from intraoral or extraoral sites (Group 2)
Number of subjects: 30
Study: 8742916

Group type: EXPERIMENTAL
Intervention: Vasopressin (0.3 U/min)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Vasopressin (0.3 U/min) plus nasal oxygen (4 L/min)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 1655647

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (50 ng x kg-1 x min-1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 6416844

Group type: EXPERIMENTAL
Intervention: Molsidomine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Molsidomine and Propranolol
Number of subjects: 39
Study: 29885777

Group type: EXPERIMENTAL
Intervention: Pre-cART vitamin D deficiency
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Baseline selenium deficiency
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Vitamin A deficiency
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: High sCD14
Number of subjects: 270
Study: 29924184

Group type: EXPERIMENTAL
Intervention: Pilates with inspiratory training
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 27865354

Group type: EXPERIMENTAL
Intervention: 420 IU vitamin D3
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 25192333

Group type: EXPERIMENTAL
Intervention: NP001 (0.2, 0.8, 1.6, and 3.2 mg/kg, single i.v. dose)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (8 patients)
Number of subjects: 32
Study: 22281051

Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study: 20848453

Group type: EXPERIMENTAL
Intervention: NI-0401 (0.05-10 mg daily for 5 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NI-0401 (1 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17428106

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montelukast with antihistamines (loratadine or cetirizine)
Number of subjects: 0
Study: 15994144

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 298
Study: 12475674

Group type: EXPERIMENTAL
Intervention: 50 microg alprostadil
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: 100 microg alprostadil
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: 200 microg alprostadil
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: 300 microg alprostadil
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study: 9857783

Group type: EXPERIMENTAL
Intervention: Medication noncompliance and substance abuse
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Problems with both alcohol and illicit drug abuse
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Improving medication adherence in the context of integrated mental health and substance abuse treatment
Number of subjects: 331
Study: 7542829

Group type: EXPERIMENTAL
Intervention: Risperidone (mean daily dose 8 mg)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Zuclopenthixol (mean daily dose 38 mg)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 98
Study: 31564184

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy with 20 Gy in five fractions followed by four cycles of chemotherapy (FOLFOX regimen)
Number of subjects: 29
Study: 31656287

Group type: EXPERIMENTAL
Intervention: Palonosetron (PAL)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Granisetron (GRA)
Number of subjects: 70
Study: 29723460

Group type: EXPERIMENTAL
Intervention: Qilan Capsules + androgen‐deprivation therapy
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo + androgen‐deprivation therapy
Number of subjects: 246
Study: 26165256

Group type: EXPERIMENTAL
Intervention: Locked plates
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonlocked plates
Number of subjects: 60
Study: 22472905

Group type: EXPERIMENTAL
Intervention: Patient Teaching (PT) for pain management
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Relaxation/Music (RM)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Combination of PT and RM
Number of subjects: 205

Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 205
Study: 21610513

Group type: EXPERIMENTAL
Intervention: benidipine-ARB
Number of subjects: 3501

Group type: EXPERIMENTAL
Intervention: benidipine-β-blocker
Number of subjects: 3501

Group type: COMPARATOR
Intervention: benidipine-thiazide
Number of subjects: 3501

Group type: EXPERIMENTAL
Intervention: benidipine and thiazide diuretic
Number of subjects: 3501

Group type: EXPERIMENTAL
Intervention: benidipine and ARB
Number of subjects: 3501
Study: 19306978

Group type: EXPERIMENTAL
Intervention: Chest drainage
Number of subjects: 24

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 24
Study: 17972364

Group type: EXPERIMENTAL
Intervention: Continuous highly active antiretroviral therapy (HAART)
Number of subjects: 273

Group type: COMPARATOR
Intervention: 5 STIs of 1, 1, 2, 2, and 3 months' duration, each followed by 3 months of therapy
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Unboosted protease inhibitor (PI)-based HAART
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Non-nucleoside reverse transcriptase inhibitor-based HAART
Number of subjects: 273
Study: 15143085

Group type: EXPERIMENTAL
Intervention: Low-dose HER‐2/neu ICD protein vaccine (25 microg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intermediate-dose HER‐2/neu ICD protein vaccine (150 microg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: High-dose HER‐2/neu ICD protein vaccine (900 microg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: All doses of HER‐2/neu ICD protein vaccine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Follow-up after immunizations
Number of subjects: 29
Study: 11801946

Group type: EXPERIMENTAL
Intervention: TCRF turbinate treatment (mean energy 415 +/- 37 J/turbinate; n = 17)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo control (n = 5)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Unblinded examiner assessment
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Self-reported CPAP adherence
Number of subjects: 22
Study: 9494309

Group type: EXPERIMENTAL
Intervention: Perceived control over pain and taking pain medication
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Pain severity
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Satisfaction with pain relief
Number of subjects: 137
Study: 7914123

Group type: EXPERIMENTAL
Intervention: Proxodolol
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 2461906

Group type: EXPERIMENTAL
Intervention: 10% hydroxyethyl starch (HES) solution
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES) solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: 10% dextran solution
Number of subjects: 10
Study: 162674

Group type: EXPERIMENTAL
Intervention: O-(beta-hydroxyethyl) rutoside (HR)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 30033775

Group type: EXPERIMENTAL
Intervention: CARE Healthy Lifestyles intervention (includes educational workshop, informational magazine, goal setting, weekly self-monitoring, tailored feedback, prompts, team-based goals, coaching for directors)
Number of subjects: 0
Study: 29625849

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 10 U/kg/leg
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 15 U/kg/leg
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (both doses)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study: 27492676

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Accessed Housing Programs
Number of subjects: 355

Group type: COMPARATOR
Intervention: Did Not Access Housing Programs
Number of subjects: 355
Study: 24824955

Group type: EXPERIMENTAL
Intervention: sevoflurane+remifentanil (S-R)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: propofol+remifentanil (P-R)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: sevoflurane+fentanyl (S-F)
Number of subjects: 93
Study: 22100691

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 21570422

Group type: EXPERIMENTAL
Intervention: Higher worksite social support
Number of subjects: 2878
Study: 18156278

Group type: EXPERIMENTAL
Intervention: Vitek 2 automated identification and susceptibility testing device, combined with direct inoculation of blood cultures
Number of subjects: 1498

Group type: COMPARATOR
Intervention: Control arm used Vitek 1 system inoculated from subcultures
Number of subjects: 1498
Study: 16688464

Group type: EXPERIMENTAL
Intervention: Musculoskeletal pain symptoms in various body sites
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Neck pain
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Ankle or foot pain
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Concurrent pain in axial, upper limb, and lower limb areas
Number of subjects: 495
Study: 14603872

Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise training (3 days a week for 10 weeks, 20 to 45 minutes)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Nontraining subjects with diabetes
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control subjects (nontraining)
Number of subjects: 19
Study: 11012500

Group type: EXPERIMENTAL
Intervention: Isobaric 2% lidocaine 4 ml intrathecally
Number of subjects: 70

Group type: COMPARATOR
Intervention: Isobaric 2% prilocaine 4 ml intrathecally
Number of subjects: 70
Study: 9161258

Group type: EXPERIMENTAL
Intervention: Electronic anesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Local anesthesia
Number of subjects: 30
Study: 1420734

Group type: EXPERIMENTAL
Intervention: 40 mmol KCl
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 40 mmol NaCl
Number of subjects: 6

Group type: COMPARATOR
Intervention: No additional salts
Number of subjects: 6
Study: 3973246

Group type: EXPERIMENTAL
Intervention: Child management training
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined child management plus planned activities
Number of subjects: 20

Group type: COMPARATOR
Intervention: Social validation group (nonproblem children)
Number of subjects: 20
Study: 31103642

Group type: EXPERIMENTAL
Intervention: IAI 2 mg every 4 weeks (2q4)
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: IAI 2 mg every 8 weeks after 5 monthly doses (2q8)
Number of subjects: 872

Group type: COMPARATOR
Intervention: Laser treatment
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: IAI (both 2q4 and 2q8)
Number of subjects: 872
Study: 29388899

Group type: EXPERIMENTAL
Intervention: 10-session version of psychiatric management augmented with the MOTR
Number of subjects: 60

Group type: COMPARATOR
Intervention: 10-session version of psychiatric management
Number of subjects: 60
Study: 26677853

Group type: EXPERIMENTAL
Intervention: 80 % oxygen
Number of subjects: 102

Group type: COMPARATOR
Intervention: 30 % oxygen
Number of subjects: 102
Study: 25441947

Group type: EXPERIMENTAL
Intervention: Distant acupuncture (HT4)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control acupuncture (BL60)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Local acupuncture (HT3)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Naïve control group
Number of subjects: 52
Study: 23207848

Group type: EXPERIMENTAL
Intervention: Sonic irrigation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vacuum irrigation
Number of subjects: 30
Study: 19543863

Group type: EXPERIMENTAL
Intervention: Hip Resurfacing (HR)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Large-head Total Hip Arthroplasty (THA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 48
Study: 17288677

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day
Number of subjects: 212

Group type: COMPARATOR
Intervention: Sertraline 50-200 mg/day
Number of subjects: 212
Study: 15539894

Group type: EXPERIMENTAL
Intervention: Calcipotriol/betamethasone dipropionate followed by calcipotriol 50 microg/g once daily
Number of subjects: 501

Group type: COMPARATOR
Intervention: Tacalcitol 4 microg/g once daily
Number of subjects: 501
Study: 11157302

Group type: EXPERIMENTAL
Intervention: Glucagon (1 mg IV)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (1 mg IV)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Open-label glucagon (1 mg IV)
Number of subjects: 14
Study: 9691869

Group type: EXPERIMENTAL
Intervention: DCLHb 400 mg kg‐1 i.v.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (oncotically matched plasma protein substitute 4.5% i.v.)
Number of subjects: 20
Study: 8283308

Group type: EXPERIMENTAL
Intervention: Nucleotide containing diet (Impact)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard high protein enteral feeding (control)
Number of subjects: 0
Study: 2659291

Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 295
Study: 30819846

Group type: EXPERIMENTAL
Intervention: Knotted Floss (KF) technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional Flossing (CF) technique
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patient Preference
Number of subjects: 30
Study: 29536598

Group type: EXPERIMENTAL
Intervention: Nurse-led video-based educational intervention
Number of subjects: 99
Study: 26709158

Group type: EXPERIMENTAL
Intervention: Tobramycin powder for inhalation (TIP)
Number of subjects: 0
Study: 24588543

Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 500